^
    BIOMARKER:

    ER Y537S

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    Apply
    Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer (H3B-6545-A001-101)
    Phase 1/2
    H3 Biomedicine Inc.
    Recruiting
    Last update posted :
    04/12/2022
    Initiation :
    08/17/2017
    Primary completion :
    06/30/2023
    Completion :
    06/30/2023
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER Y537S • ER D538G • ESR1 mutation
    |
    H3B-6545
    Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (NCT04256941)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    03/17/2022
    Initiation :
    05/31/2019
    Primary completion :
    04/26/2023
    Completion :
    04/26/2024
    ER • PGR
    |
    ER positive • HR positive • ER mutation • ER Y537S • ER D538G • ESR1 mutation
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole
    Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (NCT03781063)
    Phase 2
    Sermonix Pharmaceuticals Inc.
    Active, not recruiting
    Last update posted :
    08/26/2021
    Initiation :
    09/20/2019
    Primary completion :
    02/01/2022
    Completion :
    02/01/2022
    HER-2 • ER
    |
    HER-2 negative • ER mutation • ER Y537S • ER D538G • ER Y537N • ESR1 mutation • ER L536Q • ER Y537C
    |
    fulvestrant • Fablyn (lasofoxifene)
    Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII)
    Phase 2
    Sermonix Pharmaceuticals Inc.
    Active, not recruiting
    Last update posted :
    07/02/2021
    Initiation :
    09/29/2020
    Primary completion :
    05/01/2022
    Completion :
    10/01/2022
    HER-2 • ER
    |
    HER-2 negative • ER mutation • ER Y537S • ER D538G • ER Y537N • ESR1 mutation • ER L536Q • ER Y537C
    |
    Verzenio (abemaciclib) • Fablyn (lasofoxifene)
    The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer (NCT03202862)
    Phase 2
    Fudan University
    Not yet recruiting
    Last update posted :
    06/29/2017
    Initiation :
    07/01/2017
    Primary completion :
    06/01/2019
    Completion :
    08/01/2019
    ER • PGR
    |
    ER mutation • ER Y537S • ER D538G • ER Y537N • ESR1 mutation • ER Y537C
    |
    fulvestrant